אוקסליפלטין מדאק 100 מג Israel - Ibrani - Ministry of Health

אוקסליפלטין מדאק 100 מג

tzamal bio-pharma ltd - oxaliplatin - אבקה להכנת תמיסה לאינפוזיה - oxaliplatin 100 mg/vial - oxaliplatin - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of primary tumor . treatment of metastatic colorectal cancer.

אוקסליפלטין מדאק 150 מג Israel - Ibrani - Ministry of Health

אוקסליפלטין מדאק 150 מג

tzamal bio-pharma ltd - oxaliplatin - אבקה להכנת תמיסה לאינפוזיה - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of primary tumor. - treatment on metastatic colateral cancer.

גליולן  Israel - Ibrani - Ministry of Health

גליולן

tzamal bio-pharma ltd - 5-aminolevulinic acid as hydrochloride - אבקה להכנת תמיסה - 5-aminolevulinic acid as hydrochloride 1.5 g - aminolevulinic acid - aminolevulinic acid - gliolan® is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (who grade iii and iv).

וסנואיד Israel - Ibrani - Ministry of Health

וסנואיד

tzamal bio-pharma ltd - tretinoin - קפסולות - tretinoin 10 mg - tretinoin - tretinoin - induction of remission in acute promyelocytic leukemia.

ריווטריל Israel - Ibrani - Ministry of Health

ריווטריל

tzamal bio-pharma ltd - clonazepam - טיפות - clonazepam 2.5 mg/ml - clonazepam - clonazepam - anti-epileptic. panic disorder.

סרוקואל 25 מג Israel - Ibrani - Ministry of Health

סרוקואל 25 מג

tzamal pharma - quetiapine as fumarate - טבליות מצופות פילם - quetiapine as fumarate 25 mg - quetiapine - quetiapine - indicated for the treatment of schizophrenia. treatment of manic episodes associated with bipolar disorder.treatment of major depressive episodes in bipolar disorders.

סרוקואל 100 מג Israel - Ibrani - Ministry of Health

סרוקואל 100 מג

tzamal pharma - quetiapine as fumarate - טבליות מצופות פילם - quetiapine as fumarate 100 mg - quetiapine - quetiapine - indicated for the treatment of schizophrenia. treatment of manic episodes associated with bipolar disorder. treatment of major depressive episodes in bipolar disorders.

סרוקואל 200 מג Israel - Ibrani - Ministry of Health

סרוקואל 200 מג

tzamal pharma - quetiapine as fumarate - טבליות מצופות פילם - quetiapine as fumarate 200 mg - quetiapine - quetiapine - indicated for the treatment of schizophrenia. treatment of manic episodes associated with bipolar disorder.treatment of major depressive episodes in bipolar disorders.

סרוקואל 300 מג Israel - Ibrani - Ministry of Health

סרוקואל 300 מג

tzamal pharma - quetiapine as fumarate - טבליות מצופות פילם - quetiapine as fumarate 300 mg - quetiapine - quetiapine - indicated for the treatment of schizophrenia. treatment of manic episodes associated with bipolar disorder.treatment of major depressive episodes in bipolar disorders.

סרוקואל אקסאר 50 מג Israel - Ibrani - Ministry of Health

סרוקואל אקסאר 50 מג

tzamal bio-pharma ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 50 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should